Geron completed planned enrollment of it's randomized Phase 2 clinical trial of imetelstat, a telomerace inhibitor, for patients with advanced non-small cell lung cancer.
We need positive news before years end, a partnering or selling of Geron's stem cell properties. That would produce an easy double in share price, maybe more. Will it happen, I think IMO soon, by July. With no real good news we stay at this level, and may go lower. Geron closed down one cent at $1.55 on 854,677 shares. The avg three month volume is 824,529.
Bought 7 more AAPL, 91 more to go, it's going to take a while.
Good luck in this rigged casino,
No comments:
Post a Comment